Moderna this week announced positive data from a phase 3 trial of its messenger RNA vaccine against seasonal influenza, which ...

The leader of the U.S. FDA's division that oversees vaccines, Vinay Prasad, overruled the recommendations of his agency's ...

The Food and Drug Administration has approved three vaccines for RSV — GSK's GSK.L Arexvy, Moderna's MRNA.O mRESVIA and ...

The healthcare sector, represented by the Health Care Select Sector SPDR Fund (NYSEARCA:XLV), underperformed the broader ...

The use of TNF-α inhibitors among patients with hidradenitis suppurativa did not affect seroconversion following mRNA vaccination for COVID-19.

The Australian researchers developed a novel mRNA-based technology capable of reaching the white blood cells where HIV lies ...

S&P 500 surges in H1 2025; explore AI leaders & ETFs for H2. Click to learn more about stocks to avoid and tips to navigate ...

The Trump administration may cut off federal funding to hospitals that provide gender-related treatments to children and ...

Moderna's new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results in a major ...

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

The virus has not yet evolved to spread efficiently between people. Excellent vaccine technology exists, but the government ...